As it happens both of this issue’s feature stories are about cancer. Marc Wortman reports on a controversial theory that holds that certain stem cells underlie cancer and that identifying these cells can lead to new possibilities for treatment. Kara Nyberg reports on a partnership between the School of Medicine and Gilead Sciences in which the pharmaceutical company underwrites research at Yale that could lead to new targets for drugs to fight cancer. Having two articles on a related topic in this issue owes more to serendipity than our editorial prescience, but starting with our autumn issue, the features in Yale Medicine will all be linked by a theme in science or medicine. This focus will allow us to explore in depth advances in science and medicine not just at Yale but around the world.